No data available.
No data available.
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | ZTS | Zoetis Inc. | 59.62 Bn | 29.27 | 7.67 | 9.24 Bn |
| 2 | TAK | Takeda Pharmaceutical Co Ltd | 57.33 Bn | 79.02 | 2.00 | 36.56 Bn |
| 3 | HLN | Haleon plc | 51.85 Bn | 33.06 | 3.83 | - |
| 4 | TEVA | Teva Pharmaceutical Industries Ltd | 39.45 Bn | 27.98 | 2.29 | 17.09 Bn |
| 5 | UTHR | UNITED THERAPEUTICS Corp | 21.54 Bn | 16.94 | 6.89 | 0.00 Bn |
| 6 | RGC | Regencell Bioscience Holdings Ltd | 16.16 Bn | -4,510.00 | 0.00 | - |
| 7 | ELAN | Elanco Animal Health Inc | 12.79 Bn | 355.14 | 2.78 | 4.32 Bn |
| 8 | NBIX | Neurocrine Biosciences Inc | 12.71 Bn | 26.56 | 4.44 | 0.42 Bn |
| Current Valuation | Value | Ind Avg | Percentile |
|---|---|---|---|
| EV to Assets EV to Assets | 0.00 | 38.12 | |
| EV to Cash from Ops. EV/CFO | -0.07 | -121.97 | |
| EV to Debt EV to Debt | 0.21 | 403.43 | |
| EV to EBIT EV/EBIT | -0.05 | -55.05 | |
| EV to EBITDA EV/EBITDA | -0.38 | -57.64 | |
| EV to Free Cash Flow [EV/FCF] EV/FCF | -0.05 | -65.56 | |
| EV to Market Cap EV to Market Cap | 0.04 | -4.24 | |
| EV to Revenue EV/Rev | 0.01 | -1,205.44 | |
| Price to Book Value [P/B] P/B | 0.06 | 43.48 | |
| Price to Earnings [P/E] P/E | -3.75 | -46.00 |
| Dividend Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio Dividend Coverage Ratio | 0.00 | 0.36 | |
| Dividend Payout Ratio % Dividend Payout Ratio % | 0.00 | 0.52 | |
| Dividend per Basic Share Div per Share (Qtr) | 0.00 | 0.07 | |
| FCF Dividend Payout Ratio % FCF Dividend Payout Ratio % | 0.00 | 4.04 | |
| Interest Coverage Interest Coverage | -9.97 | -46.13 |
| Growth Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Capex Growth (1y) % Capex Growth (1y) % | -60.75 | -154.90 | |
| Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) | 3.39 | 86,151.29 | |
| Dividend Growth (1y) % Dividend Growth (1y) % | 0.00 | 2.89 | |
| EBIAT Growth (1y) % EBIAT Growth (1y) % | 68.84 | 31.16 | |
| EBITDA Growth (1y) % EBITDA Growth (1y) % | 57.93 | 9.88 | |
| EBIT Growth (1y) % EBIT Growth (1y) % | 12.53 | 91.77 | |
| EBT Growth (1y) % EBT Growth (1y) % | 2.94 | 90.13 | |
| EPS Growth (1y) % EPS Growth (1y) % | 73.83 | -12.06 | |
| FCF Growth (1y) % FCF Growth (1y) % | -886.69 | -224.48 | |
| Gross Profit Growth (1y) % Gross Profit Growth (1y) % | 498.57 | 26.23 |
| Liquidity Ratios | Value | Ind Avg | Percentile |
|---|---|---|---|
| Asset Utilization Ratio Asset Utilization Ratio | 0.13 | 0.49 | |
| Cash Payout Ratio Cash Payout Ratio | 0.00 | 0.02 | |
| Cash Ratio Cash Ratio (Qtr) | 0.45 | 2.12 | |
| Current Ratio Curr Ratio (Qtr) | 1.82 | 3.92 | |
| Debt to Equity Ratio Debt/Equity (Qtr) | 0.01 | -1.15 | |
| Interest Cover Ratio Interest Cover Ratio | -9.97 | -46.13 | |
| Times Interest Earned Times Interest Earned | -9.97 | -46.13 |
| Profitability | Value | Ind Avg | Percentile |
|---|---|---|---|
| EBITDA Margin % EBITDA Margin % | -21.70 | -59,714.97 | |
| EBIT Margin % EBIT Margin % | -25.89 | -60,539.44 | |
| EBT Margin % EBT Margin % | -28.48 | -64,118.78 | |
| Gross Margin % Gross Margin % | 19.40 | 8,658.69 | |
| Net Profit Margin % Net Profit Margin % | -10.10 | -64,120.53 |